MITOLINE™-Designed Molecules Inhibit Inflammation in Human Cells, Paving Path to $120B Metabolic Syndrome Market
MitoCareX Bio, N2OFF’s subsidiary, reported in vitro data demonstrating its MITOLINE™-designed small molecules inhibited pro-inflammatory signaling in human immune cells. Selected candidates reduced key inflammatory markers, supporting in vivo validation targeting metabolic syndrome diseases in a market projected to reach $120B by 2030.
1. In vitro anti-inflammatory data
MitoCareX Bio assembled a focused library of MITOLINE™-powered small molecules and evaluated them in proprietary assays measuring mitochondrial function, inflammatory signaling and metabolic readouts. Selected candidates demonstrated inhibition of pro-inflammatory responses in human immune cells, reducing key markers such as cytokine release.
2. Market projections and validation plan
Inflammatory metabolic diseases represent a rapidly growing segment, with metabolic disorder therapeutics projected to surpass $120 billion by 2030. These in vitro results support advancement to in vivo validation and lead optimization across multiple metabolic syndrome-related indications.
3. MITOLINE™ platform and next steps
The MITOLINE™ algorithm creates 3D comparative models of mitochondrial carriers to identify novel small-molecule scaffolds. MitoCareX Bio plans to advance its most promising anti-inflammatory candidates into preclinical studies while expanding the discovery engine to additional mitochondrial targets.